FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/02/062206 [Registered on: 01/02/2024] Trial Registered Prospectively
Last Modified On: 24/01/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Preventive
Behavioral 
Study Design  Single Arm Study 
Public Title of Study   Prevention of medication errors in emergency settings. 
Scientific Title of Study   Development of strategies to overcome medication errors in critical care settings: An interventional study with pre and post assessment 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Akanksha Saxena 
Designation  PharmD student 
Affiliation  Manipal College of Pharmaceutical Sciences 
Address  Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy Of Higher Education, Manipal

Udupi
KARNATAKA
576104
India 
Phone  7042166676  
Fax    
Email  akanksha.mcopsma@learner.manipal.edu  
 
Details of Contact Person
Scientific Query
 
Name  Dr Girish Thunga 
Designation  Associate Professor 
Affiliation  Manipal College of Pharmaceutical Sciences 
Address  Room no:05 Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy Of Higher Education, Manipal

Udupi
KARNATAKA
576104
India 
Phone  9880151127  
Fax    
Email  girish.thunga@manipal.edu  
 
Details of Contact Person
Public Query
 
Name  Dr Girish Thunga 
Designation  Associate Professor 
Affiliation  Manipal College of Pharmaceutical Sciences 
Address  Room no:05 Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy Of Higher Education, Manipal

Udupi
KARNATAKA
576104
India 
Phone  9880151127  
Fax    
Email  girish.thunga@manipal.edu  
 
Source of Monetary or Material Support  
Department Of Pharmacy Practice, Manipal College Of Pharmaceutical Sciences, Manipal Academy Of Higher Education, Manipal 
 
Primary Sponsor  
Name  NIL 
Address  NIL 
Type of Sponsor  Other [No sponsor] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Girish Thunga  Kasturba Hospital   Room-05, Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academcy of Higher Education, Manipal
Udupi
KARNATAKA 
9880151127

girish.thunga@manipal.edu 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
KH- Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: Z048||Encounter for examination and observation for other specified reasons,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Educational module  To create awareness regarding the medication error to the health care professionals. The duration for intervention will be for a period of 6 months. 
Comparator Agent  NIL  Since it is a pre and post assessment study, there is no comparator 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  Cases involving high risk medications in critical care unit.
Only seriously ill patients will be enrolled. 
 
ExclusionCriteria 
Details  Cases not involving high risk medications and who are not willing to participate. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
The study will be helpful to identify the suitable strategy which can be implemented throughout the hospital effectively to reduce all the medication errors including administration errors, transcription errors and prescription errors. The outcomes measured in terms of percentage of types of medication errors, adverse events, length of hospital stay and mortality.  Two points (pre and post) 
 
Secondary Outcome  
Outcome  TimePoints 
NIL  NIL 
 
Target Sample Size   Total Sample Size="200"
Sample Size from India="200" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   04/02/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

BACKGROUND: A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Due to the high level of complexity in care, the severity of the patient’s condition, any underlying diseases, and the need to provide life-sustaining therapy, patients in intensive care units (ICUs) are most susceptible to exposure to incidents. High-risk (HR) medications in particular are linked to medication errors that result in severe harm, protracted hospital stays, or even fatalities. Due to lack of studies regarding reporting of medication errors in India, we aim to understand the causes and incidence of medication errors in critical care system and to reduce them through development of various suitable strategies. We plan to carefully audit the ICUs in order to identify the reasons for medication errors specially with high-risk medications, thereafter, conduct interviews with the stakeholders and develop relevant strategies which can be easily implemented in our healthcare system to reduce the chances of medication errors.

 OBJECTIVES: 1) To study the incidence, severity, outcomes, and various factors influencing the medication errors in ICU settings.

 2)Development of strategies to overcome the medication errors through qualitative interview of various stake holders.

3)Implementation and evaluation of strategies in ICU settings through pre and post interventional assessment.

 METHOD:

Inclusion and exclusion criteria:

For Patients

Inclusion criteria: Cases involving high risk medications in critical care unit. 

Only seriously ill patients will be enrolled.

Exclusion criteria: Cases not involving high risk medications and who are not willing to participate.

 For Stakeholders

Inclusion criteria: Physicians, nurses, PG students and other staff working in critical care settings.

Exclusion criteria: Physicians and nurses not working in critical care settings and not willing to participate.

Development of strategies to overcome the medication errors through qualitative interview of various stake holders, implementation, and evaluation of these strategies in the ICU settings. Detailed explanation of the process is given below. This is an interventional study which will be done for physicians and health care staff involved in critical care settings to assess the potential medication errors occurring in patients taking high risk medications.

PHASE 1: Auditing (Pre assessment): After ethical committee approval, patients who are admitted in critical care settings will be observed. Based on the inclusion and exclusion criteria, study will be explained to the patient representatives and consent will be obtained, reconsenting will be done with the patient once he is conscious. Once the patient is enrolled into the study, he will be followed from the day of admission to the day of  discharge. Observing and conducting audits of prescription and medication administration chart will be done for a period of 6 months. All the data will be collected with respect to the medication errors including administration errors, transcription errors and prescription errors in a pre-designed checklist. The outcomes measured will be types of medication errors, adverse events, length of hospital stay and mortality. Based on the collected data, medication error will be classified into different categories and correlate the factors affecting the medication errors. The data collected will be used to understand the practice and barriers related to the medication errors in critical care setting.

Our study focuses only on the medication errors that occur in relation to High risk medications. High risk medicines are those medicines that have a high risk of causing significant patient harm or death when used in error. Although errors may or may not be more common than with other medicines, the consequences of errors with these medicines can be more devastating.

 PHASE 2: Interview of stakeholders: Conducting one-on-one in depth semi structured qualitative interview from various stakeholders including physicians and nurses by using an interview guide developed based on literature review, prospective audit, and expert opinion. The stakeholders will be recruited based on the purposive sampling method. The focus of this interview is to understand the perspective of stakeholders on the different aspects like concern, need and ways to minimize the occurrence of medication errors. The interviews will be audio recorded based on their consent. The audio recordings will be transcribed verbatim and NVivo software will be used to manage the data.

 PHASE 3: Development of strategies and educational model (Post assessment): It is an educational interventional study with pre and post assessment. Based on the audits and interviews performed during phase 1, different strategies and education model will be developed to train the healthcare professionals including nurses, PG students, emergency doctors and other ICU staff. Once the model has been developed, it will be validated with the help of the experts using the proper checklist. The validated model will be submitted to the IEC before implementation.

 IMPLEMENTATION

A one-day workshop will be conducted separately for nurses, PG students, emergency doctors and other ICU staff to create awareness regarding the medication errors. The developed model will be delivered by the expert physician through the workshop to the healthcare professionals in all ICUs after taking their consent. 

The strategies developed will be implemented along with the education simultaneously. Up to a period of 6 months, all the medication errors will be assessed and compared with the phase 1 results. Informed consent will be taken first from the legally authorized representative and later reconsenting will be done when the patient is conscious.

 The change of practice will be followed for a duration of 6 months from the day of workshop in all the patients who are seriously ill and are admitted to the ICU during that period. The outcome will be assessed in terms of percentage of decrease in the medication errors compared to the pre assessment conducted in phase 1.

 OUTCOME:

The study will be helpful to identify the suitable strategy which can be implemented throughout the hospital effectively to reduce all the medication errors including administration errors, transcription errors and prescription errors. The outcomes measured in terms of percentage of types of medication errors, adverse events, length of hospital stay and mortality.

 
Close